Core2Edge Glioblastoma Model Tracks Infiltration and Transcriptional Heterogeneity

Viral Science News—A team reports a new fully human ex vivo platform designed to model how glioblastoma infiltrates the brain from a tumor core outward into distant tissue. Rather than relying on animal models that often diverge from human tumor biology, the researchers developed “Core2Edge,” a three-dimensional system intended to preserve both tumor heterogeneity and the native organization of surrounding brain.

The core idea is to implant fluorescently labeled human glioblastoma organoids (GBOs) into organotypic human brain slices. This pairing allows malignant cells to invade within a realistic brain microenvironment while maintaining the genetic integrity and cytoarchitecture of both partners. In doing so, the model targets the long-distance communication concept that underlies glioblastoma as a “whole-brain” disease.

To visualize infiltration across the full range—from the initial contact region to single-cell dispersion—the workflow combines tissue expansion with light-sheet fluorescence microscopy. Light-sheet imaging provides high-resolution, three-dimensional views across thick samples, capturing the invasive front without compressing the biological context.

Technically, Core2Edge begins with brain slice preparation, typically taking about 4–6 hours depending on how many slices are handled. The GBOs are then prepared and cultured for roughly one day for initial maintenance before staining and transplantation into the slices. After implantation, a variable culture period of up to 10 days is used to allow invasion to progress to deeper regions.

Following imaging readiness, the samples are fixed for around 8 hours to stabilize tissue architecture for downstream microscopy. Once the GBOs are prepared, the protocol as a whole runs approximately 7–12 days, bridging organoid biology with slice-based invasion dynamics.

Because GBO-derived cells can be tracked fluorescently, researchers can quantify early infiltration steps and focus on cell–cell interactions at the tumor–microenvironment interface. The platform is also positioned for mechanistic studies of invasive progression and for evaluating how therapeutic candidates affect both core invasion and edge dissemination.

Importantly for translational research, Core2Edge supports drug screening and testing in a human-relevant context, potentially reducing dependence on animal experiments for questions tied to infiltration and transcriptional variability.

By enabling comprehensive mapping of infiltration and preserving heterogeneity, Core2Edge provides a structured route to interrogate glioblastoma’s spatial biology—connecting transcriptional states with where and how tumor cells spread.